Estrogen-Containing Hormone Replacement Therapy Should Be Discontinued After Stroke
For women who have had an ischemic stroke or TIA, postmenopausal hormone therapy (with estrogen with or without a progestin) is not recommended and should be discontinued. 1
Evidence-Based Recommendation
The American Heart Association/American Stroke Association provides a Class III recommendation (Level of Evidence A) explicitly stating that hormone replacement therapy should not be used in women who have experienced stroke or TIA 1. This is the highest level of evidence against a practice, meaning it should not be done.
Key Supporting Evidence
Randomized controlled trials demonstrate harm:
The Women's Estrogen for Stroke Trial (WEST) studied 664 women with prior stroke or TIA and found:
- No reduction in stroke recurrence or death with estradiol
- 2.9-fold increased risk of fatal stroke (HR 2.9; 95% CI 0.9-9.0)
- Women who had recurrent strokes while on hormone therapy were less likely to recover 1
The Women's Health Initiative (WHI) trials showed:
- 44% increased risk of all stroke with estrogen plus progestin (HR 1.44; 95% CI 1.09-1.90)
- 53% increased risk with estrogen alone (HR 1.53; 95% CI 1.16-2.02) 1
Cardiovascular Disease Context
The guidelines for patients with acute coronary syndromes (UA/NSTEMI and STEMI) provide parallel recommendations that reinforce this approach:
- Postmenopausal women already taking hormone therapy at the time of a cardiovascular event should not continue it (Class III recommendation) 2, 3, 2, 4
- Hormone therapy should be discontinued immediately during hospitalization for acute events 2, 3, 5, 2
- The increased risk applies to both cardiovascular events and stroke 2, 3, 2
Important Clinical Nuances
Timing considerations:
- The cardiovascular guidelines note that women more than 1-2 years past initiation of hormone therapy who wish to continue for "another compelling indication" should weigh risks versus benefits 2, 3, 5, 2
- However, this exception does NOT apply to stroke patients - the stroke prevention guidelines make an unequivocal Class III recommendation without such caveats 1
Route of administration matters for primary prevention but not secondary:
- Research shows transdermal hormone therapy may have lower stroke risk than oral formulations in primary prevention 6
- However, after a stroke has occurred, no formulation is recommended - the guidelines do not distinguish between routes of administration for secondary prevention 1
Common Pitfalls to Avoid
- Do not continue hormone therapy for menopausal symptom management after stroke - the stroke risk outweighs symptomatic benefits
- Do not assume "low-dose" or transdermal preparations are safe - the prohibition applies to all forms of estrogen-containing hormone therapy
- Do not delay discontinuation - hormone therapy should be stopped immediately upon stroke diagnosis, particularly during hospitalization 2, 3, 5
Alternative Management
For menopausal symptoms in stroke survivors, consider:
- Non-hormonal therapies for vasomotor symptoms (SSRIs, SNRIs, gabapentin)
- Vaginal moisturizers and lubricants for genitourinary symptoms
- Lifestyle modifications for symptom management
The evidence is clear, consistent, and based on high-quality randomized controlled trials: discontinue all estrogen-containing hormone replacement therapy after stroke.